Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
2.600
+0.030 (1.17%)
At close: Dec 20, 2024, 4:00 PM
2.570
-0.030 (-1.15%)
After-hours: Dec 20, 2024, 4:40 PM EST
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -86.74% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CTXR stock has a target of 100, which predicts an increase of 3,746.15% from the current stock price of 2.60.
Analyst Consensus: Buy
* Price targets were last updated on Nov 12, 2024.
Analyst Ratings
The average analyst rating for CTXR stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +3,746.15% | Nov 12, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $150 | Strong Buy | Maintains | $150 | +5,669.23% | Nov 11, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $150 | Strong Buy | Maintains | $150 | +5,669.23% | Aug 19, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $150 | Strong Buy | Maintains | $150 | +5,669.23% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
40.38M
EPS This Year
-5.92
from -5.57
EPS Next Year
-0.70
from -5.92
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 96.7M | 289.0M | |||
| Avg | n/a | 40.4M | 136.1M | |||
| Low | n/a | n/a | 56.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 615.8% | |||
| Avg | - | - | 237.1% | |||
| Low | - | - | 39.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.25 | 4.99 | 19.95 | |||
| Avg | -5.92 | -0.70 | 6.57 | |||
| Low | -6.37 | -4.41 | -0.91 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.